Wikipedia

User:Lychee-coffee/COVID-19 vaccination in Mainland China

< User:Lychee-coffee

COVID-19 vaccination in Mainland China is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

As of May 2021, six vaccines in Mainland China have been approved for conditional marketing or emergency use, and can be used for vaccination by vaccination units[1].

Vaccines on order edit

As of June 10, 2021, a total of 7 vaccines in Mainland China have been approved for conditional marketing or emergency use.

Early EUA Approved Vaccines edit

Vaccine Vaccine Type Manufacturer Doses Required for Vaccination Phase III clinical trial effective rate Emergency Use Authorization Deployment Date of Listing in EUL by COVAX
Sinopharm (BBIBP-CorV) Inactivated  Sinopharm (Beijing) 2[2] 86%[3]   December 31, 2020   December 31, 2020   May 7, 2021
Sinovac (CoronaVac) Inactivated  Sinovac 2[2] 50.4% - 83.5%[4][5][6]   February 5, 2021   February 5, 2021   June 1, 2021
Sinopharm (WIBP-CorV) Inactivated  Sinopharm (Wuhan) 2[2] 72.8%[7]   February 25, 2021   February 25, 2021   No
CanSino (Convidecia) Adenoviridae  CanSino 1[2] 65.7%[8]   February 25, 2021   February 25, 2021   No
Anhui Zhifei (ZF2001)[9] Protein subunit  Anhui Zhifei 3[2] [10]   March 10, 2021   March 10, 2021   No

Others Vaccines Authorised after May 2021 edit

Vaccine Vaccine Type Manufacturer Doses Required for Vaccination Emergency Use Authorization Deployment
可维克 Inactivated 康泰生物 2   2021年05月14日批准紧急使用   2021年06月01日開始接種
科维福 Inactivated 中国医学科学院医学生物学研究所 2   2021年06月09日批准紧急使用   2021年06月09日開始接種

See also edit

Reference edit

China vaccination

 

This article about the COVID-19 pandemic is a stub. You can help Wikipedia by expanding it.

 

This China-related article is a stub. You can help Wikipedia by expanding it.

 

This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it.

  1. ^ "新冠病毒疫苗接种问答来了！涉及34个关键问题". 中国新闻网. 2021-04-01. Retrieved 2021-04-02.
  2. ^ a b c d e "新冠病毒疫苗接种问答来了！涉及34个关键问题". 中国新闻网. 2021-04-01. Retrieved 2021-04-02.
  3. ^ "National Health Regulatory Authority approves Sinopharm COVID-19 vaccine". BNA. 2020-12-13. Archived from the original on 2021-02-14. Retrieved 2021-02-14.
  4. ^ "Sinovac: Brazil results show Chinese vaccine 50.4% effective". BBC News. 2021-01-13. Archived from the original on 2021-03-10. Retrieved 2021-03-13.
  5. ^ "Turkey set to receive 'effective' COVID-19 vaccine amid calls for inoculation". Daily Sabah. 2020-12-25. Archived from the original on 2021-01-08. Retrieved 2021-03-13.
  6. ^ "Indonesia grants emergency use approval to Sinovac's vaccine, local trials show 65% efficacy". The Straits Times. 2021-01-11. Archived from the original on 2021-01-30. Retrieved 2021-03-13.
  7. ^ Al Kaabi, Nawal; Zhang, Yuntao; Xia, Shengli; Yang, Yunkai; Al Qahtani, Manaf M.; Abdulrazzaq, Najiba; Al Nusair, Majed; Hassany, Mohamed; Jawad, Jaleela S. (2021-05-26). "Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial". JAMA. doi:10.1001/jama.2021.8565. ISSN 0098-7484.
  8. ^ "CanSinoBIO's COVID-19 vaccine 65.7% effective in global trials, Pakistan official says". Reuters. 2021-02-08. Retrieved 2021-02-08.
  9. ^ "智飞生物业绩看上去很美，但撑得起3000亿市值吗？". 界面新闻. 2021-04-20. Retrieved 2021-04-20.
  10. ^ "智飞生物冠病疫苗临床结果显示有效率达97%". 联合早报 (in Simplified Chinese). 2021-03-26. Retrieved 2021-04-03.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Lychee-coffee/COVID-19_vaccination_in_Mainland_China&oldid=1029855059"